Literature DB >> 24281134

Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study.

John G Cleland1, Karen Chiswell, John R Teerlink, Susanna Stevens, Mona Fiuzat, Michael M Givertz, Beth A Davison, George A Mansoor, Piotr Ponikowski, Adriaan A Voors, Gad Cotter, Marco Metra, Barry M Massie, Christopher M O'Connor.   

Abstract

BACKGROUND: Acute heart failure is a common reason for admission, and outcome is often poor. Improved prognostic risk stratification may assist in the design of future trials and in patient management. Using data from a large randomized trial, we explored the prognostic value of clinical variables, measured at hospital admission for acute heart failure, to determine whether a few selected variables were inferior to an extended data set. METHODS AND
RESULTS: The prognostic model included 37 clinical characteristics collected at baseline in PROTECT, a study comparing rolofylline and placebo in 2033 patients admitted with acute heart failure. Prespecified outcomes at 30 days were death or rehospitalization for any reason; death or rehospitalization for cardiovascular or renal reasons; and, at both 30 and 180 days, all-cause mortality. No variable had a c-index>0.70, and few had values>0.60; c-indices were lower for composite outcomes than for mortality. Blood urea was generally the strongest single predictor. Eighteen variables contributed independent prognostic information, but a reduced model using only 8 items (age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, serum sodium, urea, creatinine, and albumin) performed similarly. For prediction of all-cause mortality at 180 days, the model c-index using all variables was 0.72 and for the simplified model, also 0.72.
CONCLUSIONS: A few simple clinical variables measured on admission in patients with acute heart failure predict a variety of adverse outcomes with accuracy similar to more complex models. However, predictive models were of only moderate accuracy, especially for outcomes that included nonfatal events. Better methods of risk stratification are required. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00328692 and NCT00354458.

Entities:  

Keywords:  acute heart failure; mortality; randomized controlled trial

Mesh:

Substances:

Year:  2013        PMID: 24281134     DOI: 10.1161/CIRCHEARTFAILURE.113.000284

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  33 in total

Review 1.  Decision-making under uncertainty in advanced heart failure.

Authors:  Theo E Meyer; Michael S Kiernan; David D McManus; Jeffrey Shih
Journal:  Curr Heart Fail Rep       Date:  2014-06

2.  Provider Connectedness to Other Providers Reduces Risk of Readmission After Hospitalization for Heart Failure.

Authors:  Alon Geva; Karen L Olson; Chunfu Liu; Kenneth D Mandl
Journal:  Med Care Res Rev       Date:  2017-07-08       Impact factor: 3.929

Review 3.  Adenosine, type 1 receptors: role in proximal tubule Na+ reabsorption.

Authors:  W J Welch
Journal:  Acta Physiol (Oxf)       Date:  2014-11-11       Impact factor: 6.311

4.  Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF.

Authors:  Alberto Palazzuoli; Gaetano Ruocco; Matteo Beltrami; Ranuccio Nuti; John G Cleland
Journal:  Clin Res Cardiol       Date:  2018-03-12       Impact factor: 5.460

5.  Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure.

Authors:  Joanne Simpson; Pardeep S Jhund; Lars H Lund; Sandosh Padmanabhan; Brian L Claggett; Li Shen; Mark C Petrie; William T Abraham; Akshay S Desai; Kenneth Dickstein; Lars Køber; Milton Packer; Jean L Rouleau; Guenther Mueller-Velten; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray
Journal:  JAMA Cardiol       Date:  2020-04-01       Impact factor: 14.676

6.  Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF).

Authors:  Marat Fudim; Kishan S Parikh; Allison Dunning; Adam D DeVore; Robert J Mentz; Phillip J Schulte; Paul W Armstrong; Justin A Ezekowitz; W H Wilson Tang; John J V McMurray; Adriaan A Voors; Mark H Drazner; Christopher M O'Connor; Adrian F Hernandez; Chetan B Patel
Journal:  Am J Cardiol       Date:  2018-08-03       Impact factor: 2.778

Review 7.  Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review.

Authors:  Elke Platz; Allison A Merz; Pardeep S Jhund; Ali Vazir; Ross Campbell; John J McMurray
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

Review 8.  Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.

Authors:  Annamaria Iorio; Andrea Pozzi; Michele Senni
Journal:  Curr Heart Fail Rep       Date:  2017-06

9.  Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.

Authors:  Robert J Mentz; Eric J Velazquez; Marco Metra; Colleen McKendry; Karen Chiswell; Mona Fiuzat; Michael M Givertz; Adriaan A Voors; John R Teerlink; Christopher M O'Connor
Journal:  Future Cardiol       Date:  2015-09-25

10.  Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction.

Authors:  Lindsey Aurora; Edward Peterson; Hongsheng Gui; Nicole Zeld; James McCord; Yigal Pinto; Bernard Cook; Hani N Sabbah; L Keoki Williams; James Snider; David E Lanfear
Journal:  Clin Chim Acta       Date:  2020-09-12       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.